Key Details
Annual ROE
-94.07%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
May 11, 2023Recent annual earnings:
Mar 10, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Screeners with ZEAL included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Similar stocks
Company announcement – No. 1 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, January 13, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no.
Company announcement – No. 53 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 25, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no.
Company announcement – No. 52 / 2024 Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. Copenhagen, Denmark, 25 December 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no.
Company announcement – No. 51 / 2024 U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome The FDA concluded that Zealand Pharma's application did not meet the full requirements for substantial evidence to establish the efficacy and safety of the to-be-marketed dose of glepaglutide.
Company announcement – No. 50 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, November 11, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no.
Company announcement – No. 47 / 2024 Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on survodutide's groundbreaking results from Phase II study Boehringer launches two Phase III studies of survodutide, LIVERAGE in adults with MASH and moderate or advanced fibrosis (stages 2 or 3), and LIVERAGE-Cirrhosis in those with MASH and cirrhosis (stage 4) Copenhagen, Denmark, October 8, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
Company announcement – No. 45 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, September 12, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no.
Company announcement – No. 43 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, August 30, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no.
Company announcement – No. 41 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, August 22, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no.
Company announcement – No. 40 / 2024 Zealand Pharma major shareholder announcement: Bank of America Corporation Copenhagen, Denmark, 16 August 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no.
FAQ
- What is the primary business of Zealand Pharma A/S?
- What is the ticker symbol for Zealand Pharma A/S?
- Does Zealand Pharma A/S pay dividends?
- What sector is Zealand Pharma A/S in?
- What industry is Zealand Pharma A/S in?
- What country is Zealand Pharma A/S based in?
- When did Zealand Pharma A/S go public?
- Is Zealand Pharma A/S in the S&P 500?
- Is Zealand Pharma A/S in the NASDAQ 100?
- Is Zealand Pharma A/S in the Dow Jones?
- When was Zealand Pharma A/S's last earnings report?
- When does Zealand Pharma A/S report earnings?